hotspot -WSS

hotspot

author：entertainment 2025-09-28 16:35:12 - browse：5

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： HHS names first

WSS

Apple Watch's A

Heart disease and mental health: A look at cardiac psychology

Google says AlphaFold 3 can map a vast universe of biomolecules

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

The high cost of giving birth even with insurance

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

ChatGPT in medicine: STAT answers readers' burning questions

Telehealth startups turn to complex chronic diseases

Peter Hotez and the public health issue of online harassment

New Medicare drug pricing powers could soon be upended in court

Jerome Adams on the need for new antivirals for Covid

Heart disease and mental health: A look at cardiac psychology

Cancer drug shortages should be causing more outrage

CDC wastewater surveillance dashboard to track bird flu hotspots

focus

DeSantis can now import cheaper drugs. But will Biden get credit?

Software glitch causes Tandem insulin pump to shutdown, FDA warns

GSK to buy asthma

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Generative AI mines health records to identify patients’ social needs

The SUPPORT Act is critical to fighting the opioid crisis

Wikipedia

focus

focus

leisure time